IMVT on Nasdaq

Immunovant, Inc.

American biological products company based in New York, listed on Nasdaq (IMVT).

Price unavailable

Last updated Oct 18, 2026.

Overview

-$505.6MNet income, fiscal 2026²

Compare with another stock.

TickerIMVT on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE³
Business address1000 Park Forty Plaza, Durham, Nc 27713³
Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-59.3%Return on equity²

-$407.3MFree cash flow²

Financial statements

Net income⁴⁵⁶⁷⁸²-$505.6M in 2026+1668% since 2019

Every line of the income statement as filed: the last 3 fiscal years, latest first.²

Period ending	2026-03-31	2025-03-31	2024-03-31
Research and development	$456.7M	$360.9M	$212.9M
Acquired in-process research and development	$0	$0	$12.5M
General and administrative	$76.2M	$77.2M	$57.3M
Total operating expenses	$532.9M	$438.2M	$282.7M
Interest income, net	-$25.3M	-$24.7M	-$24.9M
Other (income) expense, net	-$2.2M	-$471.0K	$1.0M
Loss before provision for income taxes	-$505.4M	-$412.9M	-$258.8M
Provision for income taxes	$215.0K	$891.0K	$567.0K
Net loss	-$505.6M	-$413.8M	-$259.3M
Net loss per common share basic (in dollars per share)	-$2.77	-$2.73	-$1.88
Net loss per common share diluted (in dollars per share)	-$2.77	-$2.73	-$1.88
Weighted average common shares outstanding basic (in shares)	182.4M shares	151.6M shares	138.1M shares
Weighted average common shares outstanding diluted (in shares)	182.4M shares	151.6M shares	138.1M shares

Total assets⁴⁵⁶⁷¹²⁸²$957.0M in 2026+6821% since 2019

Total liabilities⁴⁵⁶⁷¹²⁸²$104.4M in 2026+1509% since 2019

Shareholders’ equity⁵⁶⁷⁸²$852.6M in 2026+11517% since 2019

Cash⁴⁵⁶⁷¹²⁸²$902.1M in 2026+12815% since 2019

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.²

Period ending	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Cash and cash equivalents	$902.1M	$714.0M
Accounts receivable	$1.1M	$2.1M
Prepaid expenses and other current assets	$42.8M	$51.2M
Income tax receivable	$2.8M	$427.0K
Total current assets	$948.8M	$767.7M
Operating lease right-of-use assets	$72.0K	$98.0K
Property and equipment, net	$443.0K	$844.0K
Other assets	$7.7M	$7.6M
Total assets	$957.0M	$776.2M
Accounts payable	$7.5M	$17.7M
Accrued expenses	$96.6M	$50.7M
Current portion of operating lease liabilities	$72.0K	$98.0K
Due to Roivant Sciences Ltd.	$175.0K	$273.0K
Total current liabilities	$104.4M	$68.8M
Total liabilities	$104.4M	$68.8M
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025	$20.0K	$16.0K
Additional paid-in capital	$2.6B	$1.9B
Accumulated other comprehensive income	$730.0K	$1.5M
Accumulated deficit	-$1.7B	-$1.2B
Total stockholders equity	$852.6M	$707.4M	$617.8M	$362.5M
Total liabilities and stockholders equity	$957.0M	$776.2M
Preferred stock, par value (in dollars per share)	$0.00
Preferred stock, authorized (in shares)	10.0M shares
Common stock, par value (in dollars per share)	$0	$0
Common stock, authorized (in shares)	500.0M shares	500.0M shares
Common stock, issued (in shares)	203.9M shares	170.1M shares
Common share, outstanding (in shares)	203.9M shares	170.1M shares

Period ending	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Cash and cash equivalents	$902.1M	$714.0M
Accounts receivable	$1.1M	$2.1M
Prepaid expenses and other current assets	$42.8M	$51.2M
Income tax receivable	$2.8M	$427.0K
Total current assets	$948.8M	$767.7M
Operating lease right-of-use assets	$72.0K	$98.0K
Property and equipment, net	$443.0K	$844.0K
Other assets	$7.7M	$7.6M
Total assets	$957.0M	$776.2M
Accounts payable	$7.5M	$17.7M
Accrued expenses	$96.6M	$50.7M
Current portion of operating lease liabilities	$72.0K	$98.0K
Due to Roivant Sciences Ltd.	$175.0K	$273.0K
Total current liabilities	$104.4M	$68.8M
Total liabilities	$104.4M	$68.8M
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025	$20.0K	$16.0K
Additional paid-in capital	$2.6B	$1.9B
Accumulated other comprehensive income	$730.0K	$1.5M
Accumulated deficit	-$1.7B	-$1.2B
Total stockholders equity	$852.6M	$707.4M	$617.8M	$362.5M
Total liabilities and stockholders equity	$957.0M	$776.2M
Preferred stock, par value (in dollars per share)	$0.00
Preferred stock, authorized (in shares)	10.0M shares
Common stock, par value (in dollars per share)	$0	$0
Common stock, authorized (in shares)	500.0M shares	500.0M shares
Common stock, issued (in shares)	203.9M shares	170.1M shares
Common share, outstanding (in shares)	203.9M shares	170.1M shares

Cash from operations⁴⁵⁶⁷⁸²-$407.3M in 2026+1327% since 2019

Capital spending⁴⁵⁶⁷⁸²$8.0K in 2026−85% since 2019

Free cash flow⁴⁵⁶⁷⁸²-$407.3M in 2026+1324% since 2019

Every line of the cash flow as filed: the last 3 fiscal years, latest first.²

Period ending	2026-03-31	2025-03-31	2024-03-31
Net loss	-$505.6M	-$413.8M	-$259.3M
Stock-based compensation	$55.7M	$49.5M	$41.1M
Depreciation on property and equipment	$409.0K	$377.0K	$231.0K
Non-cash lease expense	$99.0K	$133.0K	$1.1M
Accounts receivable	$986.0K	$3.2M	-$4.6M
Prepaid expenses and other current assets	$8.8M	-$27.0M	$1.6M
Income tax receivable	-$2.4M	-$261.0K	$19.0K
Other assets	$69.0K	-$7.7M	$0
Accounts payable	-$10.3M	$10.7M	$5.8M
Accrued expenses	$45.0M	$8.9M	$1.3M
Operating lease liabilities	-$99.0K	-$138.0K	-$1.2M
Due to Roivant Sciences Ltd.	-$98.0K	$255.0K	-$329.0K
Net cash used in operating activities	-$407.3M	-$375.9M	-$214.2M
Purchases of property and equipment	-$8.0K	-$759.0K	-$360.0K
Net cash used in investing activities	-$8.0K	-$759.0K	-$360.0K
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement	$544.2M	$450.0M	$472.7M
Payment of offering and private placement costs	-$504.0K	-$319.0K	-$6.0M
Proceeds from stock options exercised	$52.1M	$4.8M	$5.7M
Net cash provided by financing activities	$595.8M	$454.5M	$472.4M
Effect of exchange rate changes on cash and cash equivalents	-$299.0K	$747.0K	$993.0K
Net change in cash and cash equivalents	$188.1M	$78.6M	$258.8M
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	$73.0K	$98.0K	$91.0K
Income taxes	$2.4M	$1.2M	$509.0K

Compare Immunovant, Inc. with another company

Leadership

Who has led Immunovant, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Roderick Wong2019

Chief financial officer

Chief operating officer

Melanie Gloria2024–now

20202025

Chief executive officerEric Venker Jul 30, 2025 to now¹³
Chief executive officerRoderick Wong May 9, 2019 to Dec 13, 2019¹⁴
Chief executive officerPeter Salzmann Dec 20, 2019 to Jul 30, 2025¹⁵
PresidentRoderick Wong May 9, 2019 to May 9, 2019¹⁴
Chief financial officerTiago Girao Apr 28, 2025 to now¹⁶
Chief financial officerEva Renee Barnett Oct 5, 2021 to Apr 28, 2025¹⁷
Chief financial officerNaveen Yalamanchi May 9, 2019 to May 9, 2019¹⁸
Chief financial officerConnealy Pamela Yanchik Dec 20, 2019 to Mar 23, 2021¹⁹
Chief operating officerMelanie Gloria Nov 20, 2024 to now²⁰

Board members and other officers (26)

Chief Medical Officer*Michael Geffner Jan 16, 2024 to now²¹
Chief Technology OfficerJay S. Stout Apr 19, 2023 to now²²
Chief Medical OfficerRita Jain Jan 14, 2021 to Mar 31, 2021²³
Chief Medical OfficerWilliam L. Macias Jun 10, 2021 to Feb 21, 2025²⁴
Chief Scientific OfficerMichael James Elliott Aug 27, 2020 to Mar 23, 2021²⁵
VPO, Secretary and TreasurerAlice Lee May 9, 2019 to May 9, 2019²⁶
VP of CSCStephanie A. Sirota May 9, 2019 to May 9, 2019²⁷
Chief Dev. & Tech. OfficerJulia G. Butchko Dec 20, 2019 to Aug 23, 2024²⁸
Chief Medical OfficerRobert K. Zeldin Dec 20, 2019 to Dec 20, 2019²⁹
Board memberJake Bauer Apr 28, 2025 to now³⁰
Board memberRobert Graham Susman Apr 28, 2025 to now³¹
Board memberEric Venker Feb 19, 2020 to now³²
Board memberGeorge Migausky V. May 9, 2019 to now³³
Board memberGotham Makker May 9, 2019 to May 9, 2019³⁴
Board memberMark Schoenebaum May 9, 2019 to May 9, 2019³⁵
Board memberNaveen Yalamanchi May 9, 2019 to May 9, 2019¹⁸
Board memberPedro P. Granadillo May 9, 2019 to May 9, 2019³⁶
Board memberRoderick Wong May 9, 2019 to Dec 13, 2019¹⁴
Board memberSukumar Nagendran May 9, 2019 to May 9, 2019³⁷
Board memberDrew J. Fromkin Dec 20, 2019 to now³⁸
Board memberAtul Pande Dec 20, 2019 to now³⁹
Board memberDouglas J. Hughes Dec 20, 2019 to now⁴⁰
Board memberFrank Torti Dec 20, 2019 to now⁴¹
Board memberPeter Salzmann Dec 20, 2019 to now¹⁵
General counselTuyl Christopher Van Dec 18, 2024 to now⁴²
General counselW. Bradford Middlekauff Dec 20, 2019 to May 18, 2020⁴³

Former names

Health Sciences Acquisitions CorpJan 23, 2019 to Dec 20, 2019³

Timeline

Jul 30, 2025New chief executive Eric Venker becomes CEO¹³
Dec 20, 2019New chief executive Peter Salzmann becomes CEO¹⁵
May 9, 2019New chief executive Roderick Wong becomes CEO¹⁴

Filings

411 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 269 insider forms, 11 large holders, 1 private raises, 57 other. The latest 20:

Oct 9, 20264 EDGAR
Oct 9, 20264 EDGAR
Oct 9, 20264 EDGAR
Oct 5, 20264 EDGAR
Sep 25, 20264 EDGAR
Sep 3, 20268-K EDGAR
Aug 28, 20264 EDGAR
Aug 21, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 6, 202610-Q EDGAR
Aug 6, 20268-K EDGAR
Jul 24, 20264 EDGAR
Jul 24, 20264 EDGAR
Jul 24, 20264 EDGAR
Jul 22, 2026ARS EDGAR
Jul 22, 2026DEFA14A EDGAR
Jul 22, 2026DEF 14A EDGAR
Jul 10, 20264 EDGAR
Jul 10, 20264 EDGAR
Jul 10, 20264 EDGAR

The 411 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 11 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jan 15, 2025Raised $450 million in a private offering of equity Form D: 11 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	16,186,469	$623.7M	0.0%	−761,419
Deep Track Capital, LP	9,341,151	$359.9M	5.3%	−2,185,820
BlackRock, Inc.	7,180,897	$276.7M	0.0%	+606,400
Farallon Capital Management, L.l.c.	5,805,000	$223.7M	1.3%	+4,259,000
Baker Bros. Advisors LP	5,435,220	$209.4M	1.1%	−22,661
State Street Corp	4,617,005	$177.9M	0.0%	+79,076
Morgan Stanley	4,534,833	$174.7M	0.0%	+657,956
TCG Crossover Management, LLC	4,457,988	$171.8M	4.1%	No change
Vanguard Portfolio Management LLC	3,910,509	$150.7M	0.0%	+205,604
Vanguard Capital Management LLC	3,638,681	$140.2M	0.0%	+18,631
Jennison Associates LLC	3,310,238	$127.5M	0.1%	+113,533
Rtw Investments, LP	3,177,849	$122.4M	1.0%	No change
Two Seas Capital LP	3,148,505	$121.3M	4.6%	−53,457
ADAR1 Capital Management, LLC	2,330,716	$89.8M	4.3%	−348,294
Geode Capital Management, LLC	2,234,602	$86.1M	0.0%	+142,500
Woodline Partners LP	1,975,869	$76.1M	0.2%	No change
Goldman Sachs Group Inc	1,751,183	$67.5M	0.0%	−33,924
Armistice Capital, LLC	1,736,000	$66.9M	1.9%	−1,828,916
Alpine Global Management, LLC	1,375,000	$53.0M	8.7%	−1,261,925
Perceptive Advisors LLC	1,357,383	$52.3M	0.8%	−240,000
D. E. Shaw & Co., Inc.	1,240,654	$47.8M	0.0%	New
Bank Of America Corp /de/	1,181,452	$45.5M	0.0%	+287,774
Susquehanna International Group, Llp	1,022,513	$39.4M	0.0%	+404,706
Aberdeen Group plc	857,030	$33.0M	0.0%	−303,732
Northern Trust Corp	794,004	$30.6M	0.0%	+121,230

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARImmunovant, Inc. filings on SEC EDGAR
2
SEC EDGARImmunovant, Inc. 10-K for fiscal 2026
3
SEC EDGARImmunovant, Inc. filings on SEC EDGAR
4
SEC EDGARImmunovant, Inc. 10-K for fiscal 2019
5
SEC EDGARImmunovant, Inc. 10-K for fiscal 2020
6
SEC EDGARImmunovant, Inc. 10-K for fiscal 2021
7
SEC EDGARImmunovant, Inc. 10-K for fiscal 2022
8
SEC EDGARImmunovant, Inc. 10-K for fiscal 2023
9
SEC EDGARImmunovant, Inc. 10-Q for fiscal 2025
10
SEC EDGARImmunovant, Inc. 10-Q for fiscal 2025
11
SEC EDGARImmunovant, Inc. 10-Q for fiscal 2026
12
SEC EDGARImmunovant, Inc. 10-K for fiscal 2023
13
SEC EDGAREric Venker, Chief executive officer
14
SEC EDGARRoderick Wong, Chief executive officer
15
SEC EDGARPeter Salzmann, Chief executive officer
16
SEC EDGARTiago Girao, Chief financial officer
17
SEC EDGAREva Renee Barnett, Chief financial officer
18
SEC EDGARNaveen Yalamanchi, Chief financial officer
19
SEC EDGARConnealy Pamela Yanchik, Chief financial officer
20
SEC EDGARMelanie Gloria, Chief operating officer
21
SEC EDGARMichael Geffner, Chief Medical Officer*
22
SEC EDGARJay S. Stout, Chief Technology Officer
23
SEC EDGARRita Jain, Chief Medical Officer
24
SEC EDGARWilliam L. Macias, Chief Medical Officer
25
SEC EDGARMichael James Elliott, Chief Scientific Officer
26
SEC EDGARAlice Lee, VPO, Secretary and Treasurer
27
SEC EDGARStephanie A. Sirota, VP of CSC
28
SEC EDGARJulia G. Butchko, Chief Dev. & Tech. Officer
29
SEC EDGARRobert K. Zeldin, Chief Medical Officer
30
SEC EDGARJake Bauer, Board member
31
SEC EDGARRobert Graham Susman, Board member
32
SEC EDGAREric Venker, Board member
33
SEC EDGARGeorge Migausky V., Board member
34
SEC EDGARGotham Makker, Board member
35
SEC EDGARMark Schoenebaum, Board member
36
SEC EDGARPedro P. Granadillo, Board member
37
SEC EDGARSukumar Nagendran, Board member
38
SEC EDGARDrew J. Fromkin, Board member
39
SEC EDGARAtul Pande, Board member
40
SEC EDGARDouglas J. Hughes, Board member
41
SEC EDGARFrank Torti, Board member
42
SEC EDGARTuyl Christopher Van, General counsel
43
SEC EDGARW. Bradford Middlekauff, General counsel